3654 results for «600»
3654 results
Optimal timing of aspirin discontinuation: when early is too early?
20 May 2026 – From EuroPCR 2026
This session critically evaluates the optimal timing for aspirin discontinuation after PCI, discussing outcomes of aspirin-free strategies initiated within one month versus three months post-procedure. It considers differential effects of DAPT duration based on ACS presentation and bleeding risk, supported by meta-analyses and real-world data to...
New TAVI platforms - Novel devices, early data
20 May 2026 – From EuroPCR 2026
Explore the latest developments in TAVI technology, featuring novel valve platforms and early clinical data. The session covers outcomes from new self-expandable and balloon-expandable valves, innovative single-operator techniques, redo TAVI approaches, and advances in CT sizing powered by deep learning.
TAVI: new approach
20 May 2026 – From EuroPCR 2026
This session introduces new frontiers in transcatheter aortic valve implantation (TAVI), including artificial intelligence-enabled systems and minimalist, radiation-free approaches guided by echocardiography. It covers complex procedural techniques such as axillary access under TEE guidance, precision snaring, and managing challenging anatomies, emphasizing advancements in safety and efficacy...
Registries and trials in mitral TEER
20 May 2026 – From EuroPCR 2026
This comprehensive session reviews registries and clinical trials in mitral transcatheter edge-to-edge repair (TEER). It includes discussions on novel TEER systems, international consensus on PASCAL implants, anatomical predictors of procedural success, and long-term outcomes including ventricular and atrial remodeling after intervention, as well as emerging therapies...
AI in imaging & the cathlab - opportunities in procedural planning & guidance
20 May 2026 – From EuroPCR 2026
This session explores the role of artificial intelligence in imaging and the cathlab, emphasizing computer vision applications distinct from language models. It discusses AI's integration into procedural planning and guidance, balancing algorithmic support with physician judgement to enhance interventional cardiology workflows.
Imaging the calcified lesions: what you need to see
20 May 2026 – From EuroPCR 2026
This session emphasizes critical imaging aspects necessary for assessing calcified coronary lesions. It addresses lesion-specific Agatston scoring, OCT-guided PCI optimization, coronary CT planning, histopathological insights, and predictors of stent underexpansion after calcium modification.
CTO PCI in images and case examples: what is new in 2026?
07 Jul 2026
Register for free to this webinar on Monday 31 August at 6:00pm with K. Mashayekhi, M. Ayoub and C. Ungureanu and learn to review the recent evidence on expected outcomes after CTO PCI, and much more!
Primary Outcomes of a Pivotal Multicenter Randomized Trial Comparing the AGENT Paclitaxel-Coated Ballon with Conventional Ballon Angioplasty for In-Stent Restenosis (AGENT IDE)
27 Oct 2023
Mirvat Alasnag provides her take on the AGENT IDE trial which was presented by Robert W. Yeh at TCT Congress 2023. This pivotal randomized trial compares the safety and efficacy of the AGENT DCB to conventional balloon angioplasty in patients with ISR. It is the first...
Author
The greatest advance in the next 40 years would be to remove the need for angioplasty
17 May 2017
Spencer B. King performed some of the first coronary angioplasty procedures in the USA—having recently received a thank-you from the first patient that he treated. He tells The Daily Wire that the steerable guidewire, rather than the stent, was the greatest advance in angioplasty and that...
Authors :
ALL-RISE: A large-scale, global randomized trial of coronary physiology derived from conventional angiography compared with an invasive pressure wire-based approach to guide PCI
28 Mar 2026
Mirvat Al Asnag provides her take on the ALL-RISE randomised trial presented by Ajay J. Kirtane at ACC.26 in New Orleans.
Author
The AQUATIC trial: Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation
01 Sep 2025
Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.
Author
![The AQUATIC trial [Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial]](https://www.pcronline.com/var/pcrov3/storage/images/pcronline/news/congress-coverages/esc/2025/aquatic-trial-quitting-versus-using-aspirin-therapy-patients-stabilized-cad-stenting-long-term-oral-anticoagulation/27448089-9-eng-GB/The-AQUATIC-trial-Assessment-of-quitting-versus-using-aspirin-therapy-in-patients-with-stabilized-coronary-artery-disease-after-stenting-who-requi_image_responsive_6.jpg)
From PROTECT-AF to CHAMPION-AF: Where do we stand today?
01 Jul 2026
In this article, Jens Erik Nielsen-Kudsk reviews the evolution of left atrial appendage closure, from early trials such as PROTECT‑AF to recent evidence including CHAMPION‑AF, and discusses its expanding role in stroke prevention for atrial fibrillation.
Author
A randomized, placebo-controlled trial of chronic total occlusion PCI in stable angina - ORBITA-CTO trial
03 Apr 2026
Kalaivani Mahadevan provides an in-depth analysis of the ORBITA-CTO trial: a first-ever randomised, double-blind, placebo-controlled trial evaluating CTO PCI in stable angina patients.
She also interviewed principal investigators Sarosh Khan and John Davies following the LBCT Scientific Session at ACC.26 in New Orleans and simultaneous publication in...
Author
Author
Author
COVID-19 vaccines: Burning questions from the community and real-world applicability
13 Jan 2021
View a number of questions of interest to the interventional cardiovascular community, as well as the real-world applicability of COVID-19 vaccine trials.
